|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Obese mice exhibited fasting hyperglycemia, hyperinsulinemia, and impaired glucose tolerance, as well as decreased serum levels of adiponectin and increased levels of leptin, resistin, and insulin-like growth factor 1.
|
30867005 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We found that the serum ADMA and C-reactive protein levels were significantly increased in IGT and diabetic patients, whereas the levels of lipoprotein A and adiponectin were decreased, especially in diabetic patients with obesity.
|
30536533 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Treatment with all doses of Eriomin (200, 400, and 800 mg) had similar effects and altered significantly the following variables: blood glucose (-5%), insulin resistance (-7%), glucose intolerance (-7%), glycated hemoglobin (-2%), glucagon (-6.5%), C-peptide (-5%), hsCRP (-12%), interleukin-6 (-13%), TNFα (-11%), lipid peroxidation (-17%), systolic blood pressure (-8%), GLP-1 (+15%), adiponectin (+19%), and antioxidant capacity (+6%).
|
31183921 |
2019 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
At 3-year postpartum, they underwent cardiometabolic characterization (including measurement of estimated glomerular filtration rate (eGFR), adiponectin and NT-proBNP) and repeated the OGTT, revealing 69 women with glucose intolerance (prediabetes/diabetes).
|
29112786 |
2018 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In males, adiponectin levels were significantly lower in the IGT group compared to the non-IGT group (Whitney U test, p < 10-4), whereas leptin levels were significantly higher (p = 0.009) in IGT group.
|
30399195 |
2018 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Adiponectin levels were 59% higher in the NGT group than those in the IGT/T2DM group (<i>P</i> < 0.01).
|
29951553 |
2018 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Type 2 diabetes risk, early impaired glucose tolerance and insulin resistance were predicted with >98% specificity and sensitivity by comparing fasting glucose levels to the estimated Matsuda Index based on fasting levels of insulin, adiponectin and leptin with or without oxidative lineolate metabolites.
|
29610560 |
2018 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Regression models and receiver operator curves were used to evaluate the association between midpregnancy adiponectin and hsCRP and persistent impaired glucose tolerance.
|
29078256 |
2018 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
HF dams had greater fat mass, higher plasma leptin, lower plasma adiponectin, and impaired glucose tolerance during pregnancy.
|
28332771 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Subjects with normal glucose tolerance (NGT, n=108), impaired glucose tolerance (IGT, n=92), and newly diagnosed type 2 diabetes mellitus (nT2DM, n=106) were recruited to determining the circulating CTRP9 and adiponectin levels by enzyme linked immunosorbent assay.
|
28743061 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, insulin resistance and glucose intolerance induced by HFD were distinctly improved, and adiponectin concentration in the blood was notably increased.
|
28333098 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
At baseline, adiponectin, cathepsin D and NCAM.L1 (proteins expressed by pancreatic β-cells) were significantly lower in those that progressed to IGT.
|
28846711 |
2017 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Suppressing DNMT1 activity with a DNMT inhibitor resulted in the amelioration of obesity-induced glucose intolerance and insulin resistance in an adiponectin-dependent manner.
|
26139044 |
2015 |
|
Impaired glucose tolerance
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The SNP276G>T polymorphism in the adiponectin gene has been reported to be associated with type 2 diabetes and impaired glucose tolerance.
|
23885987 |
2013 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Phlebotomy of humans with impaired glucose tolerance and ferritin values in the highest quartile of normal increased adiponectin and improved glucose tolerance.
|
22996660 |
2012 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our aim was to study the association of the ADIPOQ variations with body weight, serum adiponectin concentrations and conversion to T2DM in overweight subjects with impaired glucose tolerance.
|
21219602 |
2011 |
|
Impaired glucose tolerance
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The analyses showed that age (P < 0.0001), BMI (P < 0.0001), and six variants (IGF2BP2 rs4402960, P = 0.002; ADIPOQ+276 G>T, P = 0.004; UCP2Ala55Val, P = 0.01; CDKN2AI2B rs3731201, P = 0.02; rs495490, P = 0.02, and rsl 0811661, P = 0.03) were significantly associated with the risk of IFG/IGT/T2DM.
|
20384434 |
2010 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Adiponectin knockout mice manifest glucose intolerance, insulin resistance, and hyperlipidemia and tend to develop malignancies especially when on high-fat diets.
|
19906806 |
2010 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action.
|
17706206 |
2008 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus.
|
18492757 |
2008 |
|
Impaired glucose tolerance
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In a case-control design we compared levels of eight immune mediators and adiponectin from patients with IGT/T2DM (n=52) and normal glucose tolerance (NGT; n=59).
|
18777458 |
2008 |
|
Impaired glucose tolerance
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our findings are the first to indicate that a higher incidence of impaired glucose tolerance and low circulating adiponectin concentration may be associated with interaction between the -308G/A promoter polymorphism of the TNF-alpha gene and SNP 45 in the adiponectin gene.
|
16254197 |
2006 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We assessed circulating adiponectin and AdipoR1/R2 mRNA expression in human skeletal muscle in a cross-sectional study of 140 subjects with normal or impaired glucose tolerance or type 2 diabetes.
|
16551730 |
2006 |
|
Impaired glucose tolerance
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These data suggest that pioglitazone increases plasma adiponectin levels by posttranscriptional regulation in contrast to transcriptional regulation of adiponectin in relation to insulin sensitivity in NGT vs. IGT subjects.
|
16118250 |
2006 |
|
Impaired glucose tolerance
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up study.
|
16788799 |
2006 |